Fig. 7.
Signatures of BTN3A3 and LSECtin abundance in the breast cancer. a Btn3a3 mRNA expression in non-TNBC and TNBC samples from the TCGA data set (non-TNBC n = 824; TNBC n = 105). b Real-time PCR analysis showing Btn3a3 expression with cDNAs from non-TNBC patients (n = 16, black) and TNBC patients (n = 12, red) as templates. c Kaplan–Meier survival curve of breast cancer patients from the TCGA data set (For non-TNBC samples, BTN3A3low: 60%, n = 496, BTN3A3high: 40%, n = 328; for TNBC samples, BTN3A3low: 60%, n = 64, BTN3A3high: 40%, n = 41). d Manders coefficient of LSECtin and CD68 in non-TNBC and TNBC clinical tumor sections. Each symbol represents a specimen. Details regarding the tumor pathology are presented in Supplementary information, Table S1. e Correlation between Lsectin expression and TAM-associated gene expression in human TNBC samples from GSE76250 data set (n = 165). Data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 (unpaired Student’s t test for a, b, d). See also Supplementary information, Fig. S7